. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18 MeV Alpha-particles |
|
|
Cyclotron-produced alpha-particles |
|
|
RIKEN Cyclotron at Wako-shi, Saitama |
|
|
Materials: Human peripheral blood lymphocytes |
|
|
Date: 1969.08.26 |
|
|
Ref: Sasaki, M. S., Takatsuji, T. and Ejima, Y. (1998). Radiat. Res., 150:253-258. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dose* |
No. of |
Aberrations |
Distribution of cells with indicated number of aberrations |
|
|
(Gy) |
cells |
Tet |
Tri |
Dic |
Rc |
Ra |
aM |
F |
del |
S |
del |
Aber |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
|
|
0.27 |
200 |
0 |
0 |
41 |
13 |
5 |
6 |
55 |
2 |
2 |
2 |
Dics |
169 |
22 |
8 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D+R |
164 |
21 |
10 |
3 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All |
161 |
23 |
8 |
5 |
1 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0.54 |
240 |
0 |
1 |
84 |
29 |
11 |
15 |
118 |
7 |
30 |
27 |
Dics |
175 |
49 |
12 |
3 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D+R |
161 |
47 |
21 |
8 |
2 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All |
147 |
50 |
21 |
11 |
8 |
|
3 |
|
|
|
|
|
|
|
|
|
|
|
1.35 |
130 |
0 |
4 |
140 |
50 |
20 |
27 |
203 |
18 |
47 |
41 |
Dics |
45 |
39 |
33 |
9 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D+R |
34 |
29 |
34 |
18 |
10 |
4 |
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All |
23 |
21 |
31 |
29 |
13 |
2 |
5 |
6 |
|
|
|
|
|
|
|
|
|
|
1.62 |
230 |
1 |
10 |
267 |
63 |
39 |
44 |
367 |
28 |
75 |
64 |
Dics |
84 |
69 |
37 |
22 |
11 |
5 |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D+R |
67 |
58 |
44 |
25 |
18 |
13 |
3 |
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All |
60 |
38 |
45 |
28 |
22 |
14 |
13 |
5 |
2 |
1 |
2 |
|
|
|
|
|
|
|
2.7 |
100 |
2 |
7 |
201 |
34 |
25 |
28 |
267 |
27 |
65 |
53 |
Dics |
16 |
20 |
26 |
18 |
10 |
7 |
1 |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D+R |
10 |
18 |
23 |
20 |
11 |
10 |
4 |
|
1 |
1 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All |
8 |
11 |
19 |
14 |
9 |
15 |
9 |
4 |
4 |
3 |
1 |
2 |
|
1 |
|
|
|
|
4.05 |
30 |
2 |
10 |
90 |
21 |
12 |
21 |
118 |
9 |
31 |
19 |
Dics |
0 |
2 |
6 |
6 |
8 |
3 |
2 |
1 |
1 |
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D+R |
0 |
1 |
3 |
5 |
7 |
2 |
5 |
3 |
1 |
2 |
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All |
0 |
0 |
0 |
4 |
3 |
4 |
8 |
1 |
2 |
2 |
3 |
2 |
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*) The dose has been calculated based on the stopping power of water, in which oxygen is the major target for alpha-particle. The dose could be 62.94% higher for the ICRU muscle. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
. |